| 1 |
Boshrouyeh R, Amari S, Boshrouyeh Ghandashtani M, Alavi SE, Ebrahimi Shahmabadi H. A topical gel nanoformulation of amphotericin B (AmB) for the treatment of cutaneous leishmaniasis (CL). J Sol-Gel Sci Technol 2023. [DOI: 10.1007/s10971-023-06041-w] [Reference Citation Analysis]
|
| 2 |
Alavi SE, Panah N, Page F, Gholami M, Dastfal A, Sharma LA, Ebrahimi Shahmabadi H. Hydrogel-based therapeutic coatings for dental implants. European Polymer Journal 2022;181:111652. [DOI: 10.1016/j.eurpolymj.2022.111652] [Reference Citation Analysis]
|
| 3 |
Alavi SE, Raza A, Koohi Moftakhari Esfahani M, Akbarzadeh A, Abdollahi SH, Ebrahimi Shahmabadi H. Carboplatin Niosomal Nanoplatform for Potentiated Chemotherapy. J Pharm Sci 2022;111:3029-37. [PMID: 35675875 DOI: 10.1016/j.xphs.2022.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 4 |
Alavi SE, Raza A, Gholami M, Giles M, Al-sammak R, Ibrahim A, Ebrahimi Shahmabadi H, Sharma LA. Advanced Drug Delivery Platforms for the Treatment of Oral Pathogens. Pharmaceutics 2022;14:2293. [DOI: 10.3390/pharmaceutics14112293] [Reference Citation Analysis]
|
| 5 |
Ghaferi M, Raza A, Koohi M, Zahra W, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE. Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma. Pharmaceutics 2022;14:2183. [DOI: 10.3390/pharmaceutics14102183] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 6 |
Alavi SE, Bakht U, Koohi Moftakhari Esfahani M, Adelnia H, Abdollahi SH, Ebrahimi Shahmabadi H, Raza A. A PEGylated Nanostructured Lipid Carrier for Enhanced Oral Delivery of Antibiotics. Pharmaceutics 2022;14:1668. [DOI: 10.3390/pharmaceutics14081668] [Reference Citation Analysis]
|
| 7 |
Ghaferi M, Zahra W, Akbarzadeh A, Ebrahimi Shahmabadi H, Alavi SE. Enhancing the efficacy of albendazole for liver cancer treatment using mesoporous silica nanoparticles: an in vitro study. EXCLI J 2022;21:236-49. [PMID: 35221842 DOI: 10.17179/excli2021-4491] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 8 |
Alavi SE, Esfahani MKM, Raza A, Adelnia H, Shahmabadi HE. PEG-grafted liposomes for enhanced antibacterial and antibiotic activities: An in vivo study. NanoImpact 2022. [DOI: 10.1016/j.impact.2022.100384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 9 |
Esfahani MKM, Alavi SE, Cabot PJ, Islam N, Izake EL. PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells. Pharmaceutics 2021;13:1605. [PMID: 34683898 DOI: 10.3390/pharmaceutics13101605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 10 |
Lu L, Duong VT, Shalash AO, Skwarczynski M, Toth I. Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines. Vaccines (Basel) 2021;9:563. [PMID: 34071482 DOI: 10.3390/vaccines9060563] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 11 |
Mirnezami SMS, Heydarinasab A, Akbarzadeh A, Arjmand M. Investigation of characterization and cytotoxic effect of PEGylated nanoliposomal containing Melphalan on ovarian cancer: an in vitro study. Journal of Experimental Nanoscience 2021;16:101-15. [DOI: 10.1080/17458080.2021.1922669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 12 |
Alavi SE, Cabot PJ, Raza A, Moyle PM. Developing GLP-1 Conjugated Self-Assembling Nanofibers Using Copper-Catalyzed Alkyne-Azide Cycloaddition and Evaluation of Their Biological Activity. Bioconjug Chem 2021;32:810-20. [PMID: 33843208 DOI: 10.1021/acs.bioconjchem.1c00091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 13 |
Alavi SE, Ebrahimi Shahmabadi H. GLP-1 peptide analogs for targeting pancreatic beta cells. Drug Discov Today 2021;26:1936-43. [PMID: 33839290 DOI: 10.1016/j.drudis.2021.03.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 14 |
Park J, Bak M, Min K, Kim HW, Cho JH, Tae G, Kwon I. Effect of C-terminus Conjugation via Different Conjugation Chemistries on In Vivo Activity of Albumin-Conjugated Recombinant GLP-1. Pharmaceutics 2021;13:263. [PMID: 33672039 DOI: 10.3390/pharmaceutics13020263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 15 |
Hussain H, Wattoo FH, Wattoo MHS, Gulfraz M, Masud T, Shah I, Ali S, Alavi SE. Camel milk as an alternative treatment regimen for diabetes therapy. Food Sci Nutr 2021;9:1347-56. [PMID: 33747450 DOI: 10.1002/fsn3.2078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 16 |
Das B, Gupta P. Luminescent terpyridine appended geminal bisazide and bistriazoles: multinuclear Pt(II) complexes and AIPE-based DNA detection with the naked eye. Dalton Trans 2021;50:10225-36. [PMID: 34236066 DOI: 10.1039/d1dt01108a] [Reference Citation Analysis]
|
| 17 |
Ashrafzadeh MS, Akbarzadeh A, Heydarinasab A, Ardjmand M. In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin. Int J Nanomedicine 2020;15:7035-49. [PMID: 33061366 DOI: 10.2147/IJN.S255902] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 18 |
Ghaferi M, Koohi Moftakhari Esfahani M, Raza A, Al Harthi S, Ebrahimi Shahmabadi H, Alavi SE. Mesoporous silica nanoparticles: synthesis methods and their therapeutic use-recent advances. J Drug Target 2021;29:131-54. [PMID: 32815741 DOI: 10.1080/1061186X.2020.1812614] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 19 |
Yousefi Aldashi S, Saffari Z, Ebrahimi Shahmabadi H, Akbarzadeh A. In Vitro Assessment of Magnetic Liposomal Paclitaxel Nanoparticles as a Potential Carrier for the Treatment of Ovarian Cancer. Adv Pharm Bull 2021;11:267-73. [PMID: 33880348 DOI: 10.34172/apb.2021.039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
